Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

132.73 -1.00 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 392,298
Open 132.62
Bid (Size) 132.73 (1)
Ask (Size) 137.01 (1)
Prev. Close 133.73
Today's Range 131.69 - 133.31
52wk Range 120.64 - 160.96
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
Exposures Product Safety

Performance

YTD
-15.11%
-15.11%
1 Month
-5.32%
-5.32%
3 Month
+3.87%
+3.87%
6 Month
-3.53%
-3.53%
1 Year
-0.41%
-0.41%

More News

Read More
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via FinancialNewsMedia
Exposures Product Safety
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Industry Changes As Marijuana Rescheduling Looms
Via Benzinga
Topics Cannabis
Exposures Cannabis
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
Via Benzinga
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
Is Axsome Therapeutics Stock a Screaming Buy?
Via The Motley Fool
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
Via Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job
Via Benzinga
FDA, Get It Done! Says Senator In Bipartisan Push To Regulate CBD Products Prior To Committee Hearing
Via Benzinga
Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
Via Benzinga
4 Unequaled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Via The Motley Fool
Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful'
Via Benzinga
10 Cannabis Stocks That Could Go Sky High In 2023
Via Talk Markets
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
Via Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.